From risk to retention: using wearable hyperkalemia monitoring to sustain GDMT by Moin Hussaini, Chief Product Officer at AccurKardia
In this compelling discussion, Moin Hussaini, Chief Product Officer at AccurKardia, explores how wearable technologies and artificial intelligence are transforming the management of hyperkalemia and helping clinicians sustain Guideline-Directed Medical Therapy (GDMT) for patients with cardiovascular disease.
Discover how continuous, non-invasive monitoring can enable earlier detection of hyperkalemia, improve clinical decision-making, and support better patient outcomes.
Moin highlights the growing role of AI-powered digital health solutions in addressing one of the key challenges in cardiovascular care—keeping patients safely on life-saving therapies while minimizing treatment interruptions and adverse events.
This session offers valuable insights into the future of wearable diagnostics, remote patient monitoring, and precision cardiovascular care. Whether you’re a clinician, healthcare executive, researcher, digital health innovator, or investor, you’ll gain a deeper understanding of how emerging technologies are helping bridge the gap between risk management and long-term treatment adherence.
